“Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s108. doi:10.25251/skin.4.supp.108.